Notable Labs (NASDAQ:NTBL) Earns “Market Outperform” Rating from JMP Securities

JMP Securities restated their market outperform rating on shares of Notable Labs (NASDAQ:NTBL) in a research report sent to investors on Monday morning, Benzinga reports. JMP Securities currently has a $9.00 price objective on the stock.

Separately, Chardan Capital cut their price objective on Notable Labs from $9.00 to $7.00 and set a buy rating for the company in a research report on Monday.

Notable Labs Stock Down 2.5 %

Shares of NTBL opened at $0.96 on Monday. Notable Labs has a 52-week low of $0.83 and a 52-week high of $11.20. The firm has a market cap of $2.13 million, a P/E ratio of -0.26 and a beta of 0.77. The business has a fifty day moving average of $1.44. The company has a quick ratio of 5.65, a current ratio of 5.65 and a debt-to-equity ratio of 0.02.

Hedge Funds Weigh In On Notable Labs

An institutional investor recently bought a new position in Notable Labs stock. Industry Ventures L.L.C. bought a new stake in shares of Notable Labs, Ltd. (NASDAQ:NTBL) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 204,424 shares of the company’s stock, valued at approximately $386,000. Notable Labs accounts for 0.6% of Industry Ventures L.L.C.’s portfolio, making the stock its 6th biggest position. Industry Ventures L.L.C. owned 9.21% of Notable Labs at the end of the most recent quarter. 70.48% of the stock is owned by institutional investors and hedge funds.

Notable Labs Company Profile

Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic.